SABCS 2021

Early-Stage Breast Cancer

Aromatase inhibitors outperform tamoxifen in premenopausal women

Presented By

Ms Rosie Bradley, University of Oxford, UK

Trial

Phase 3, ABCGS12; TEXT; SOFT; HOBOE

Conference

SABCS 2021

31 January, 2022 16:49

Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer

Presented By

Dr Jeremy Braybrooke, University Hospitals Bristol NHS Foundation Trust, UK

Conference

SABCS 2021

31 January, 2022 16:44

Reduced risk of recurrence with ovarian suppression plus tamoxifen/exemestane

Presented By

Dr Meredith Regan, Dana-Farber Cancer Institute, USA

Trial

Phase 3, TEXT; SOFT

Conference

SABCS 2021

31 January, 2022 16:36

Metformin does not improve outcomes in patients with early-stage breast cancer

Presented By

Dr Pamela Goodwin, Lunenfeld-Tanenbaum Research Institute, Canada

Trial

Phase 3, CCTGMA.32

Conference

SABCS 2021

31 January, 2022 16:32

Omitting sentinel lymph node biopsy improves arm symptoms

Presented By

Prof. Bernd Gerber, University of Rostock, Germany

Trial

INSEMA

Conference

SABCS 2021

31 January, 2022 16:29

HR-positive/HER2-negative Breast Cancer

Addition of palbociclib to standard endocrine therapy does not improve outcome in adjuvant treatment

Presented By

Prof. Michael Gnant, Medical University of Vienna, Austria

Trial

Phase 3, PALLAS

Conference

SABCS 2021

31 January, 2022 17:31

The SERD elacestrant improves outcomes for patients unresponsive to endocrine therapy

Presented By

Dr Aditya Bardia, Massachusetts General Hospital, MA, USA

Trial

Phase 3, EMERALD

Conference

SABCS 2021

31 January, 2022 17:29

Consistent overall survival benefit of ribociclib in advanced breast cancer

Presented By

Prof. Lisa Carey & Dr Joyce O’Shaughnessy

Trial

Phase 3, MONALEESA

Conference

SABCS 2021

31 January, 2022 17:24

Premenopausal women benefit from adjuvant chemotherapy next to endocrine therapy

Presented By

Dr Kevin Kalinsky, Emory University Winship Cancer Institute, GA, USA

Trial

Phase 3, RxPONDER

Conference

SABCS 2021

31 January, 2022 17:19

Promising anti-tumour activity of the CDK7-inhibitor samuraciclib plus fulvestrant

Presented By

Prof. Charles Coombes, Imperial College London, UK

Conference

SABCS 2021

31 January, 2022 17:16

ctDNA is prognostic and predictive for response to ribociclib plus letrozole

Presented By

Dr Giampaolo Bianchini, San Raffaele Scientific Institute, Italy

Trial

Phase 3, BioItaLEE

Conference

SABCS 2021

31 January, 2022 17:13

Early switch to fulvestrant plus palbociclib beneficial for patients with ESR1 mutation

Presented By

Prof. François-Clément Bidard, Institut Curie, France

Trial

Phase 3, PADA-1

Conference

SABCS 2021

31 January, 2022 17:09

Triple-Negative Breast Cancer

Single-cell spatial analysis can predict response to neoadjuvant immunotherapy

Presented By

Dr Giampaolo Bianchini, Ospedale San Raffaele, Italy

Trial

Phase 3, NeoTRIPaPDL1

Conference

SABCS 2021

31 January, 2022 17:48

Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC

Presented By

Prof. Peter Schmid, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-522

Conference

SABCS 2021

31 January, 2022 17:45

Early use of ctDNA testing can identify likelihood of relapse in TNBC

Presented By

Prof. Nicholas Turner, The Institute of Cancer Research, UK

Trial

Phase 2, c-TRAK-TN

Conference

SABCS 2021

31 January, 2022 17:42

Pembrolizumab plus chemotherapy benefits patients with combined positive score ≥10

Presented By

Dr Javier Cortés, Vall d'Hebron Institute of Oncology, Spain

Trial

Phase 3, KEYNOTE-355

Conference

SABCS 2021

31 January, 2022 17:40

Neratinib plus trastuzumab plus fulvestrant shows encouraging clinical activity

Presented By

Dr Komal Jhaveri, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, SUMMIT

Conference

SABCS 2021

31 January, 2022 17:37

Phase 1–3 Trials

Datopotamab deruxtecan shows promising anti-tumour activity

Presented By

Dr Ian Krop, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 1, TROPION-PanTumor01

Conference

SABCS 2021

31 January, 2022 18:05

Trastuzumab deruxtecan outperforms trastuzumab emtansine

Presented By

Dr Sara Hurvitz, University of California, CA, USA

Trial

Phase 3, DESTINY-Breast03

Conference

SABCS 2021

31 January, 2022 18:02

Nivolumab plus ipilimumab serve promising dual checkpoint inhibition

Presented By

Dr Romualdo Barroso-Sousa , Hospital Sírio-Libanês, Brazil

Trial

Phase 2, NIMBUS

Conference

SABCS 2021

31 January, 2022 17:59

Entinostat plus exemestane improves progression-free survival in Chinese patients

Presented By

Prof. Binghe Xu, Chinese Academy of Medical Sciences, China

Conference

SABCS 2021

31 January, 2022 17:57

Efficacy of pyrotinib plus capecitabine confirmed in previously treated patients

Presented By

Prof. Binghe Xu, Chinese Academy of Medical Sciences, China

Trial

Phase 3, PHOEBE

Conference

SABCS 2021

31 January, 2022 17:54

Basic and Translational Research

Using genomics to match treatments improves outcomes

Presented By

Prof. Fabrice André, Institut Gustave Roussy, France

Trial

Phase 2, SAFIR02-BREAST; SAFIR-PI3K

Conference

SABCS 2021

31 January, 2022 22:19

How tamoxifen can induce uterine cancer

Presented By

Dr Kirsten Kübler, Broad Institute, MA, USA

Conference

SABCS 2021

31 January, 2022 22:15

Loss of ASXL1 tumour suppressor promotes resistance to CDK4/6 inhibitors

Presented By

Dr Dhivya Sudhan, UT Southwestern Medical Center, TX, USA

Conference

SABCS 2021

31 January, 2022 22:12

Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells

Presented By

Dr William Tahaney, MD Anderson Cancer Center, TX, USA

Conference

SABCS 2021

31 January, 2022 22:10

MAPK-pathway alterations are associated with resistance to anti-HER2 therapy

Presented By

Dr Emanuela Ferraro, Memorial Sloan-Kettering Cancer Center, NY, USA

Conference

SABCS 2021

31 January, 2022 22:08

Genomic signatures of DCIS define biology and correlate with clinical outcomes

Presented By

Dr Siri Strand, Stanford University, CA, USA

Trial

TBCRC 038;RAHBT

Conference

SABCS 2021

31 January, 2022 18:11

BRCA2 linked to inferior outcomes with CDK4/6 inhibitors plus endocrine therapy

Presented By

Dr Anton Safonov, Memorial Sloan-Kettering Cancer Center, NY, USA

Conference

SABCS 2021

31 January, 2022 18:08

Miscellaneous

Olaparib is well tolerated as an additional treatment

Presented By

Dr Patricia Ganz, UCLA School of Medicine, CA, USA

Trial

Phase 3, OlympiA

Conference

SABCS 2021

31 January, 2022 22:26

Race effects the likelihood to develop lymphoedema following breast cancer treatment

Presented By

Dr Andrea Barrio, Memorial Sloan-Kettering Cancer Center, NY, USA

Trial

Phase 2, I-SPY

Conference

SABCS 2021

31 January, 2022 22:25

Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection

Presented By

Dr Damiano Gentile, Humanitas Research Hospital, Italy

Trial

SINODAR ONE

Conference

SABCS 2021

31 January, 2022 22:23

One in 7 breast cancers detected during screening are overdiagnosed

Presented By

Dr Marc Ryers , Duke University Medical Center, NC, USA

Conference

SABCS 2021

31 January, 2022 22:21